Add to ORKGUpdated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000) As last year, a consensus group to consider the use of tumour necrosis factor (TNF) blocking agents was formed by an organising committee constituted of rheumatologists from the Universities of Erlangen, Leiden and Vienna in Europe in cooperation with universities in the United States. Pharmaceutical support was obtained from a number of companies, but these institutions had no part in the decisions regarding this specific programme nor with regard to the participants or attendees at this conference. The approximately 100 rheumatologists and bioscien-tists from 25 countries who attended the consensus conference were cho...
Purpose: To explore the use of the biological tumour necrosis factor alpha (TNFalpha) inhibitors use...
Pharmacological management of rheumatoid arthritis (RA) includes synthetic and biological disease-mo...
International audienceThe 2014 French Society for Rheumatology (Société Française de Rheumatologie, ...
As in previous years, the consensus group to consider the use of biological agents was constituted b...
Updated consensus statement on biological agents, specifically tumour necrosis factor a (TNFa) block...
Updated consensus statement on biological agents, specifically tumour necrosis factor a (TNFa) block...
TNF blocking agents are promising therapeutic agents for RA. Studies in selected areas of efficacy, ...
Background: Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juven...
Contains fulltext : 70534.pdf (publisher's version ) (Closed access
OBJECTIVE: To establish clinical consensus for the optimal placement of TNF inhibitor (TNFi) in DMA...
International audienceTNF-alpha has been found to play a pivotal role in the pathogenic mechanisms o...
A review. The development of inhibitors of Tumor Necrosis Factor (TNF) a, a pro-inflammatory cytoki...
A large number of experts experienced in the treatment of rheumatoid arthritis were involved in form...
Contains fulltext : 50423.pdf (publisher's version ) (Closed access
guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again) Because of ...
Purpose: To explore the use of the biological tumour necrosis factor alpha (TNFalpha) inhibitors use...
Pharmacological management of rheumatoid arthritis (RA) includes synthetic and biological disease-mo...
International audienceThe 2014 French Society for Rheumatology (Société Française de Rheumatologie, ...
As in previous years, the consensus group to consider the use of biological agents was constituted b...
Updated consensus statement on biological agents, specifically tumour necrosis factor a (TNFa) block...
Updated consensus statement on biological agents, specifically tumour necrosis factor a (TNFa) block...
TNF blocking agents are promising therapeutic agents for RA. Studies in selected areas of efficacy, ...
Background: Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juven...
Contains fulltext : 70534.pdf (publisher's version ) (Closed access
OBJECTIVE: To establish clinical consensus for the optimal placement of TNF inhibitor (TNFi) in DMA...
International audienceTNF-alpha has been found to play a pivotal role in the pathogenic mechanisms o...
A review. The development of inhibitors of Tumor Necrosis Factor (TNF) a, a pro-inflammatory cytoki...
A large number of experts experienced in the treatment of rheumatoid arthritis were involved in form...
Contains fulltext : 50423.pdf (publisher's version ) (Closed access
guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again) Because of ...
Purpose: To explore the use of the biological tumour necrosis factor alpha (TNFalpha) inhibitors use...
Pharmacological management of rheumatoid arthritis (RA) includes synthetic and biological disease-mo...
International audienceThe 2014 French Society for Rheumatology (Société Française de Rheumatologie, ...